A source of information
that few know exists
Members get the change to define and prioritize the most pressing challenges we want to tackle, as well as influence how we tackle them. Among the critical challenges your peers want to address include:

Establishing the acceptable levels of contaminants such as the double stranded RNA (dsRNA) within mRNA drug products

Discovering how to align global regulatory and safety experience in mRNA as a platform technology

Understanding which animal model elicit the most transferrable response to humans

Currently available options to increase levels of mRNA outside the liver whilst managing LNP toxicity

How do we define the platform and what allowances can be made?

Where can we leverage validation across the platform for use across other product?

What is our understanding of the control of cell banks and how are we treating plasmids as a raw material? What allowances can be made?
The feedback from members speaks for itself…
For more reviews about mRNA-Based Therapeutics: Searchlight membership, head to our testimonials page and hear directly from our members about why they've joined.
Membership brochure
For more information on what’s included as part of the mRNA-Based Therapeutics: Searchlight membership, please download the membership brochure.
Here’s what you’ll learn more about:
- The unique mission and purpose of the network
- What membership includes
- How the quarterly cornerstone meetings work
- How bespoke value delivery works
- How we deliver demonstrable value to you
- Annual member investment